[go: up one dir, main page]

FR2845385B1 - COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS - Google Patents

COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Info

Publication number
FR2845385B1
FR2845385B1 FR0212370A FR0212370A FR2845385B1 FR 2845385 B1 FR2845385 B1 FR 2845385B1 FR 0212370 A FR0212370 A FR 0212370A FR 0212370 A FR0212370 A FR 0212370A FR 2845385 B1 FR2845385 B1 FR 2845385B1
Authority
FR
France
Prior art keywords
thiohydantoin
therapeutics
compounds derived
derived
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212370A
Other languages
French (fr)
Other versions
FR2845385A1 (en
Inventor
Benaissa Boubia
Khan Ou
Evelyne Chaput
Philippe Ratel
Jean Binet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0212370A priority Critical patent/FR2845385B1/en
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to US10/529,817 priority patent/US20060025589A1/en
Priority to CA002500977A priority patent/CA2500977A1/en
Priority to JP2004540883A priority patent/JP2006510600A/en
Priority to AU2003279442A priority patent/AU2003279442A1/en
Priority to PCT/FR2003/002904 priority patent/WO2004031160A2/en
Priority to EP03772390A priority patent/EP1546111A2/en
Publication of FR2845385A1 publication Critical patent/FR2845385A1/en
Application granted granted Critical
Publication of FR2845385B1 publication Critical patent/FR2845385B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0212370A 2002-10-01 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS Expired - Fee Related FR2845385B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (en) 2002-10-04 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
CA002500977A CA2500977A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof in therapeutics
JP2004540883A JP2006510600A (en) 2002-10-04 2003-10-03 Compounds derived from 2-thiohydantoin and their use in therapy
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PCT/FR2003/002904 WO2004031160A2 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
EP03772390A EP1546111A2 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (en) 2002-10-04 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Publications (2)

Publication Number Publication Date
FR2845385A1 FR2845385A1 (en) 2004-04-09
FR2845385B1 true FR2845385B1 (en) 2004-12-31

Family

ID=32011425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212370A Expired - Fee Related FR2845385B1 (en) 2002-10-01 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Country Status (1)

Country Link
FR (1) FR2845385B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857139B2 (en) 2006-03-27 2020-12-08 The Regents Of The University Of California Substituted diazaspiroalkanes as androgen receptor modulators

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AR102942A1 (en) 2014-12-11 2017-04-05 Bayer Cropscience Ag DERIVATIVES OF ARILSULFIDE AND ARILSULPHOXIDE OF FIVE C-N-CONNECTED MEMBERS, AS PESTICIDES
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (en) * 1955-08-30
AU531493B2 (en) * 1977-12-01 1983-08-25 The Wellcome Foundation Limited Thiohydantion derivatives
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
WO1997019932A1 (en) * 1995-11-28 1997-06-05 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives and their use for increasing hdl cholesterol concentration
BR0013671A (en) * 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Heterocyclic Derivatives for the Treatment of Diabetes and Other Diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857139B2 (en) 2006-03-27 2020-12-08 The Regents Of The University Of California Substituted diazaspiroalkanes as androgen receptor modulators
US11771687B2 (en) 2006-03-27 2023-10-03 The Regents Of The University Of California Substituted diazaspiroalkanes as androgen receptor modulators

Also Published As

Publication number Publication date
FR2845385A1 (en) 2004-04-09

Similar Documents

Publication Publication Date Title
EP1624935A4 (en) ANTI-ADHERENCE COMPOSITES AND METHODS OF USING THE SAME
EG23770A (en) Thin and dry diaper
IL171501A (en) Genetically modified dermal micro-organs and use of the same
EP1971600A4 (en) ISOXASOLE DERIVATIVES AND THEIR USE
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
DE60118618D1 (en) BELLY POLYMER ELECTROLYTE AND RELATED USE
GB0401363D0 (en) Hinge unit and hinge structure using the same
EP1831207A4 (en) AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
DE60238980D1 (en) Improvements in radiolocation systems
FR2845384B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
EP1514679A4 (en) MATTE THIN FILM RIAU AND ASSOCIATE PR PARATION PROC D
EP1625111A4 (en) THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF
PT1513836E (en) PIPERAZINILACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
EP1476150A4 (en) CARBOXYFULLERENES AND METHODS OF USE THEREOF
GB0607619D0 (en) Processor surrogate for use in multiprocessor systems and multiprocessor system using same
EP1633749A4 (en) DEAZAFLAVIN COMPOUNDS AND METHODS OF USE
DE60319724D1 (en) ULTICAST ABILITY IN AN ATM NETWORK
FR2845385B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
FR2838960B1 (en) COMPOSITION COMPRISING PHOTOCHROMES AND USE THEREOF IN COSMETICS
FR2845383B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
AU2003272011A8 (en) Solid and semi-solid polymeric ionic conjugates
FR2843945B1 (en) STACKABLE AND ENCASTRABLE BIN
NO990256L (en) Polymer blends, their preparation and use
EP1786431A4 (en) IMPROVED PHOTOSENSIBILIZER PREPARATIONS AND USE THEREOF

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070629